Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04050293 · ClinicalTrials.gov registry record · Phase 4
Therapy for Migraine Prevention in Children 6-11 Years of Age
A Phase 4 study, sponsored by Supernus Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT04050293 is a Phase 4 study that was terminated before completion, run by Supernus Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT04050293, a Phase 4 study, was terminated before completion, sponsored by Supernus Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the effect of SPN-538 for the prophylaxis of migraine in pediatric patients 6 to 11 years old.
Interventions
- DRUG Placebo
- DRUG SPN-538
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-07-14 |
| Est. Completion | 2023-03-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04050293
The ClinicalTrials.gov registry entry for NCT04050293 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04050293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04050293 about?
NCT04050293 is a clinical study titled "Therapy for Migraine Prevention in Children 6-11 Years of Age". The aim of this study is to evaluate the effect of SPN-538 for the prophylaxis of migraine in pediatric patients 6 to 11 years old.
What is the current status of trial NCT04050293?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2020-07-14. Estimated completion is 2023-03-01.
What interventions are being tested in trial NCT04050293?
The interventions under investigation include: Placebo (DRUG), SPN-538 (DRUG).
Who is sponsoring clinical trial NCT04050293?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.